Nano-cap stock, Aptose Biosciences $APTO plunged in response to its announcement that the FDA�s clinical hold on its Phase 1b clinical trial evaluating lead product candidate APTO-253 will continue until it submits additional data. The regulatory authority put the candidate on clinical hold in November 2015 after problems with an IV infusion pump surfaced at a clinical trial site.